EWP
MDGL icon

Elevation Wealth Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Elevation Wealth Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9
Closed -$2.72K – 875
2025
Q2 		$2.72K Hold
9
– – ﹤0.01% 425
2025
Q1 		$2.98K Hold
9
– – ﹤0.01% 427
2024
Q4 		$2.78K Hold
9
– – ﹤0.01% 433
2024
Q3 		$1.91K Hold
9
– – ﹤0.01% 424
2024
Q2 		$2.52K Hold
9
– – ﹤0.01% 437
2024
Q1 		$2.4K Buy
+9
New +$2.12K ﹤0.01% 413

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Elevation Wealth Partners's MDGL Position: Q3 2025 in Review

Elevation Wealth Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2025, closing a stake of 9 shares — an estimated $2.72K sold.

Elevation Wealth Partners first reported a position in MDGL in Q1 2024 and held it in 6 quarters. The position peaked at $2.98K in Q1 2025. 352 funds tracked by Wall St. Rank hold MDGL as of Q3 2025.

  • Elevation Wealth Partners reported no remaining Madrigal Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Elevation Wealth Partners sold 9 Madrigal Pharmaceuticals shares in Q3 2025, an estimated $2.72K.
  • Elevation Wealth Partners first reported a position in Madrigal Pharmaceuticals in Q1 2024 and held it in 6 quarters.
  • Elevation Wealth Partners's Madrigal Pharmaceuticals position peaked at $2.98K in Q1 2025.
  • 352 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2025.

Based on Elevation Wealth Partners's 13F filing for Q3 2025, filed 6 Oct 2025.